Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Teva Pharmaceutical Industries ADR
(NY:
TEVA
)
14.10
-0.33 (-2.32%)
Streaming Delayed Price
Updated: 12:34 PM EDT, Mar 28, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Teva Pharmaceutical Industries ADR
< Previous
1
2
3
4
5
6
7
8
9
...
15
16
Next >
Cramer Isn't 'Knocking' This Pharma Firm Anymore: 'As A Matter Of Fact, I'm Going In'
March 25, 2024
Raymond James Financial, Inc. (NYSE: RJF) is now valued more highly than JPMorgan Chase & Co. (NYSE: JPM), according to Jim Cramer.
Via
Benzinga
Senator Bernie Sanders Applauds GSK's Move To Cap Inhaler Costs At $35 Per Month
March 21, 2024
GSK caps asthma and COPD medicine costs at $35/month, effective Jan 1, 2025. Includes Advair, Breo, Ventolin. Follows AstraZeneca's suit for their respiratory medicines. Sanders applauds move amid...
Via
Benzinga
The Generic Drugs Antitrust Case
March 16, 2024
Imagine that in the market for generic drugs, a group of companies form a cartel to raise prices on the products controlled by their group. What pattern might you expect to see for the prices of...
Via
Talk Markets
8 Analysts Assess Teva Pharmaceutical Indus: What You Need To Know
March 08, 2024
Via
Benzinga
Week In Review: Mabwell Sells Ex-China Rights To Rare Disease Therapy In $412 Million Deal
March 02, 2024
Mabwell, a Shanghai-San Diego biotech, sold ex-China rights for 9MW3011 to Disc Medicine of Watertown, MA in a deal worth up to $412 million. Meanwhile, AstraZeneca has returned most of the global...
Via
Talk Markets
Beyond The Numbers: 8 Analysts Discuss Teva Pharmaceutical Indus Stock
February 12, 2024
Via
Benzinga
A Preview Of Teva Pharmaceutical Indus's Earnings
January 30, 2024
Via
Benzinga
Drug Maker Organon Stock Scores Relative Strength Upgrade
February 28, 2024
In a welcome move, drug maker Organon stock saw its Relative Strength Rating rise from 66 to 71 on Wednesday.
Via
Investor's Business Daily
Why Freshpet Shares Are Trading Higher By Around 15%? Here Are Other Stocks Moving In Monday's Mid-Day Session
February 26, 2024
Shares of Freshpet, Inc. (NASDAQ: FRPT) gained 15.5% to $106.29 after the company reported better-than-expected fourth-quarter financial results.
Via
Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
February 26, 2024
Via
Benzinga
Ethereum Price Predictions: Where Will the ETH Crypto Go After Retaking $3,000?
February 26, 2024
Ethereum price predictions are a hot topic on Monday as crypto traders wonder where the token will go after surpassing $3,000.
Via
InvestorPlace
Jefferies Just Raised Its Price Target on Salesforce (CRM) Stock
February 26, 2024
Salesforce stock is rising higher on Monday after CRM shares got an increased price target from Jefferies analysts this morning.
Via
InvestorPlace
TEVA Stock Pops 4% as Teva Receives FDA Approval
February 26, 2024
Teva Pharmaceutical stock is rising higher on Monday after partner company Alvotech got approval from the FDA for a Humira biosimilar.
Via
InvestorPlace
Exposures
Product Safety
Why Is Generic Drugs Player Teva Pharma Stock Trading Higher Today?
February 26, 2024
FDA-approved Simlandi (adalimumab-ryvk): a high-concentration biosimilar to Humira for rheumatoid arthritis, psoriasis, and more.
Via
Benzinga
Li Auto Posts Q4 Earnings, Joins Teva Pharmaceutical And Other Big Stocks Moving Higher In Monday's Pre-Market Session
February 26, 2024
U.S. stock futures were lower this morning, with the Dow futures trading lower by over 50 points on Monday.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
MAIA Biotechnology: Undervalued With Eye-Popping Cancer Data And Partnership Potential
February 22, 2024
MAIA Biotechnology, a biotechnology company developing innovative cancer treatments, has seen its stock drift downwards for the past months.
Via
Talk Markets
Teva Pharma CEO Dismisses Split Speculations Expects Significant Interest For Its API Business Divestiture: Report
February 20, 2024
Teva Pharmaceutical Industries confirms unity and dispels split rumors. CEO Richard Francis emphasizes the synergy between generics and branded drugs.
Via
Benzinga
Why This Teva Pharmaceutical Analyst Is Turning Bullish On The Austedo Franchise
February 12, 2024
Shares of Teva Pharmaceutical Industries Ltd (NYSE: TEVA) climbed in early trading on Monday, after several analysts raised their forecasts.
Via
Benzinga
CymaBay Therapeutics, ContextLogic, Snap And Other Big Stocks Moving Higher On Monday
February 12, 2024
U.S. stocks were mixed, with the Nasdaq Composite trading almost flat on Monday. Shares of CymaBay Therapeutics, Inc. (NASDAQ: CBAY) rose sharply in today’s pre-market trading.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Teva Pharmaceutical To Rally Around 58%? Here Are 10 Top Analyst Forecasts For Monday
February 12, 2024
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
Via
Benzinga
3 Biotech Stocks to Buy for the Next Bull Run: February 2024
February 08, 2024
These are the biotech stocks to buy that you must have on your watchlist for the coming bull run. It could get started as soon as this month.
Via
InvestorPlace
Teva Pharmaceutical Industries (TEVA) Q4 2023 Earnings Call Transcript
January 31, 2024
TEVA earnings call for the period ending December 31, 2023.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
Boeing Posts Upbeat Results, Joins Stryker, Automatic Data Processing And Other Big Stocks Moving Higher On Wednesday
January 31, 2024
U.S. stocks traded mostly lower, with the Nasdaq Composite falling over 200 points on Wednesday.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Generic Drug Player Teva Pharma To Divest Its Active Pharmaceutical Ingredient Business, Q4 Earnings Surpass Estimates
January 31, 2024
Teva Pharmaceutical surpasses Q4 2023 sales expectations, reporting $4.46 billion. Teva plans to divest API business for revenue optimization. Outlook for FY 2024.
Via
Benzinga
Teva Sinks On Lackluster Profit Outlook Despite Walloping Quarterly Projections
January 31, 2024
Teva Pharmaceutical easily beat fourth-quarter views, but its 2024 profit guidance left something to be desired.
Via
Investor's Business Daily
Nasdaq Futures Plummet As Alphabet, AMD Disappointments Sour Sentiment; Spotlight Shifts To Fed Statement, Powell's Presser
January 31, 2024
The record run of the market faces risk as the big tech earnings season got off to a negative start, casting cloud on profit outlook.
Via
Benzinga
Topics
Economy
Exposures
Interest Rates
Earnings Scheduled For January 31, 2024
January 31, 2024
Companies Reporting Before The Bell • Novartis (NYSE:NVS) is likely to report quarterly earnings at $1.68 per share on revenue of $11.56 billion.
Via
Benzinga
Stocks Mixed Ahead Of Big Tech Earnings
January 30, 2024
Stocks are a mixed bag this afternoon, following the start of the Federal Reserve's two-day policy meeting.
Via
Talk Markets
Topics
Economy
Exposures
Interest Rates
Tech Titans Microsoft, Apple Lead 'Magnificent Seven' Earnings Wave This Week: Can Mega-Caps Ignite Market Optimism?
January 29, 2024
An analyst sees the Satya Nadella-led company's earnings to be the key barometer for AI spending.
Via
Benzinga
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Enphase Energy To Rally Over 35%? Here Are 10 Top Analyst Forecasts For Tuesday
January 23, 2024
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
...
15
16
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.